Quarterly ResultAug 3, 2026, 07:07 AM
Krystal Biotech Q2 Revenue +24.1% to $119.2M; EPS $1.79
AI Summary
Krystal Biotech, Inc. reported strong financial results for the second quarter and first half of 2026, driven by increased product revenue from VYJUVEK. Product revenue for Q2 2026 grew 24.1% year-over-year to $119.2 million, leading to a 42.9% increase in net income to $54.8 million and diluted EPS of $1.79. The company maintains a robust liquidity position with $845.6 million in cash and short-term investments, which is expected to fund operations for at least the next 12 months. The filing also noted ongoing legal proceedings, including a DOJ subpoena and a patent inventorship lawsuit.
Key Highlights
- Product revenue for Q2 2026 increased 24.1% to $119.2 million from $96.0 million in Q2 2025.
- Net income for Q2 2026 rose 42.9% to $54.8 million, up from $38.3 million in Q2 2025.
- Diluted EPS for Q2 2026 was $1.79, a 38.8% increase compared to $1.29 in Q2 2025.
- Product revenue for the six months ended June 30, 2026, grew 27.9% to $235.6 million.
- Net income for the six months ended June 30, 2026, increased 49.5% to $110.7 million.
- Cash and cash equivalents stood at $427.7 million as of June 30, 2026.
- Operating cash flow for the six months ended June 30, 2026, was $155.2 million, up from $83.7 million.
- US product revenue for Q2 2026 was $91.6 million, Europe $19.3 million, and Japan $8.3 million.
Price Impact
More from KRYS